Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 positive, a BRAF inhibitor with or without a MEK inhibitor.
Safety and efficacy were evaluated in a global, multicenter, multicohort,